Re-evaluating Transarterial Chemoembolization Failure/Refractoriness:A Survey by Chinese College of Interventionalists  

作　　者：Bin-Yan Zhong Wan-Sheng Wang Shen Zhang Hai-Dong Zhu Lei Zhang Jian Shen Xiao-Li Zhu Gao-Jun Teng Cai-Fang Ni 

机构地区：[1]Department of Interventional Radiology,the First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China [2]Center of Interventional Radiology&Vascular Surgery,Department of Radiology,Zhongda Hospital,Medical School,Southeast University,Nanjing,Jiangsu,China

出　　处：《Journal of Clinical and Translational Hepatology》2021年第4期521-527,共7页临床与转化肝病杂志（英文版）

基　　金：This study was supported by the National Natural Science Foundation of China(No.81901847,81520108015 and 81827805);the Clinical Innovation Center of Medical Imaging and Interventional Radiology(No.YXZXA2016005);the Natural Science Foundation of Jiangsu Province(No.BK20190177);and the Suzhou Science and Technology Youth Plan(No.KJXW2018003);Funding sources had no involvement in the financial support for the conduct of the research and preparation of the article。

摘　　要：Background and Aims:The recognition of transarterial chemoembolization(TACE)failure/refractoriness among Chinese clinicians remains unclear.Using an online survey conducted by the Chinese College of Interventionalists(CCI),the aim of this study was to explore the recognition of TACE failure/refractoriness and review TACE application for hepatocellular carcinoma(HCC)treatment in clinical practice.Methods:From 27 August 2020 to 30 August 2020 during the CCI 2020 annual meeting,a survey with 34 questions was sent by email to 264 CCI clinicians in China with more than 10 years of experience using TACE for HCC treatment.Results:A total of 257 clinicians participated and responded to the survey.Most participants agreed that the concept of“TACE failure/refractoriness”has scientific and clinical significance(n=191,74.3%).Nearly half of these participants chose TACE-based combination treatment as subsequent therapy after so-called TACE failure/refractoriness(n=88,46.1%).None of the existing TACE failure/refractoriness definitions were widely accepted by the participants;thus,it is necessary to re-define this concept for the treatment of HCC in China(n=235,91.4%).Most participants agreed that continuing TACE should be performed for patients with preserved liver function,presenting portal vein tumor thrombosis(n=242,94.2%)or extrahepatic spread(n=253,98.4%),after the previous TACE treatment to control intrahepatic lesion(s).Conclusions:There is an obvious difference in the recognition of TACE failure/refractoriness among Chinese clinicians based on existing definitions.Further work should be carried out to re-define TACE failure/refractoriness.

关 键 词：Hepatocellular carcinoma TACE FAILURE REFRACTORINESS SURVEY 

分 类 号：X70[环境科学与工程—环境工程]